• Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.

      Cuzick, Jack; Warwick, Jane; Pinney, Elizabeth; Duffy, Stephen W; Cawthorn, Simon; Howell, Anthony; Forbes, John F; Warren, Ruth M L; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. j.cuzick@qmul.ac.uk (2011-05-04)
      Mammographic breast density is a strong risk factor for breast cancer. Tamoxifen, which reduces the risk of breast cancer in women at high risk, also reduces mammographic breast density. However, it is not known if tamoxifen-induced reductions in breast density can be used to identify women who will benefit the most from prophylactic treatment with this drug.
    • Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

      de Boer, Richard H; Arrieta, Óscar; Yang, Chih-Hsin; Gottfried, Maya; Chan, Valorie; Raats, Johann; de Marinis, Filippo; Abratt, Raymond P; Wolf, Jürgen; Blackhall, Fiona H; et al. (2011-03-10)
      Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This randomized, placebo-controlled phase III study assessed the efficacy of vandetanib plus pemetrexed as second-line therapy in advanced non-small-cell lung cancer.